Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
BVS Quote, Financials, Valuation and Earnings
Last price:
$8.96
Seasonality move
:
20.11%
Day range:
$8.73 - $9.05
52-week range:
$5.81 - $9.53
Dividend yield:
0%
P/E ratio:
26.80x
P/S ratio:
1.05x
P/B ratio:
3.21x
Volume:
318.4K
Avg. volume:
430.6K
1-year change:
-5.68%
Market cap:
$591.4M
Revenue:
$568.1M
EPS (TTM):
$0.33
Analysts' Opinion
-
Consensus RatingBioventus, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.80, Bioventus, Inc. has an estimated upside of 64.99% from its current price of $8.97.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $8.97.
Fair Value
-
According to the consensus of 3 analysts, Bioventus, Inc. has 64.99% upside to fair value with a price target of $14.80 per share.
BVS vs. S&P 500
-
Over the past 5 trading days, Bioventus, Inc. has underperformed the S&P 500 by -6.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bioventus, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bioventus, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bioventus, Inc. reported revenues of $157.9M.
Earnings Growth
-
Bioventus, Inc. has grown year-over-year earnings for 6 quarters straight. In the most recent quarter Bioventus, Inc. reported earnings per share of $0.21.
Enterprise value:
908.7M
EV / Invested capital:
--
Price / LTM sales:
1.05x
EV / EBIT:
15.83x
EV / Revenue:
1.60x
PEG ratio (5yr expected):
-0.41x
EV / Free cash flow:
12.73x
Price / Operating cash flow:
8.38x
Enterprise value / EBITDA:
8.70x
Gross Profit (TTM):
$382.4M
Return On Assets:
3.88%
Net Income Margin (TTM):
4.8%
Return On Equity:
13.53%
Return On Invested Capital:
4.99%
Operating Margin:
13.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $512.3M | $573.3M | $568.1M | $153.6M | $157.9M | |
| Gross Profit | $319.4M | $380.6M | $382.4M | $100.9M | $107.5M | |
| Operating Income | $16.9M | $45.4M | $57.4M | $13.7M | $21.7M | |
| EBITDA | $74.3M | $95M | $104.4M | $26.1M | $33.4M | |
| Diluted EPS | -$2.51 | -$0.56 | $0.33 | -$0.01 | $0.21 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $263.1M | $272.6M | $268M | $275.6M | $272.8M | |
| Total Assets | $1.2B | $1.4B | $810.9M | $728M | $683.6M | |
| Current Liabilities | $180.9M | $304M | $175.5M | $210.4M | $160.4M | |
| Total Liabilities | $692.1M | $960.4M | $589.8M | $542.4M | $455.1M | |
| Total Equity | $533.8M | $412.2M | $221.1M | $185.6M | $228.4M | |
| Total Debt | $372.7M | $432.4M | $405.4M | $353M | $308M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $15.3M | $37.6M | $74M | $19.3M | $37.3M | |
| Cash From Investing | $15.8M | $23M | -$3.2M | $24.1M | -$580K | |
| Cash From Financing | -$26.7M | -$53.4M | -$61.4M | -$42.9M | -$27.8M | |
| Free Cash Flow | $8M | $35.9M | $71.4M | $18.7M | $36.7M | |
BVS
Sector
Market Cap
$591.4M
$23.9M
Price % of 52-Week High
94.12%
47.44%
Dividend Yield
0%
0%
Shareholder Yield
2.92%
-1.9%
1-Year Price Total Return
-5.68%
-18.29%
Beta (5-Year)
0.696
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.09
200-day SMA
Buy
Level
$7.47
Bollinger Bands (100)
Buy
Level
7.4 - 8.68
Chaikin Money Flow
Buy
Level
1.9M
20-day SMA
Buy
Level
$8.91
Relative Strength Index (RSI14)
Buy
Level
52.91
ADX Line
Sell
Level
16.17
Williams %R
Neutral
Level
-45.1613
50-day SMA
Buy
Level
$8.58
MACD (12, 26)
Buy
Level
0.15
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Neutral
Level
77.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.2833)
Sell
CA Score
(Annual)
Level (-0.9908)
Buy
Beneish M-Score
(Annual)
Level (-2.8025)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-0.1868)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
Stock Forecast FAQ
In the current month, BVS has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BVS average analyst price target in the past 3 months is $14.80.
-
Where Will Bioventus, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bioventus, Inc. share price will rise to $14.80 per share over the next 12 months.
-
What Do Analysts Say About Bioventus, Inc.?
Analysts are divided on their view about Bioventus, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bioventus, Inc. is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Bioventus, Inc.'s Price Target?
The price target for Bioventus, Inc. over the next 1-year time period is forecast to be $14.80 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is BVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bioventus, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BVS?
You can purchase shares of Bioventus, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bioventus, Inc. shares.
-
What Is The Bioventus, Inc. Share Price Today?
Bioventus, Inc. was last trading at $8.96 per share. This represents the most recent stock quote for Bioventus, Inc.. Yesterday, Bioventus, Inc. closed at $8.97 per share.
-
How To Buy Bioventus, Inc. Stock Online?
In order to purchase Bioventus, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get BVS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
BVS
Sector
P/E ratio
26.80x
21.37x
PEG ratio
-0.41x
-0.01x
P/B ratio
3.21x
1.72x
Price / LTM sales
1.05x
1.44x
Growth Metrics
BVS
Sector
Revenue growth
2.77%
3.44%
Earnings growth
3710.17%
14.97%
Revenue (5-year growth)
12.08%
6.27%
Earnings forecast
$0.10
-$0.22
Profitability
BVS
Sector
Profitability FY 2025
$382.4M
$2.4M
Return on invested capital
4.99%
-33.43%
Return on assets
3.88%
-29.45%
Return on equity
13.53%
-40.29%
Earnings Date
Last Earnings Date
Mar
5
Next Earnings Date
May
5
Estimated Next Earnings Date
Jun
4
Balance Sheet
BVS
Sector
Total cash
$51.2M
$25.6M
Short term investments
--
$22.7M
Total assets
$683.6M
$70.4M
Long term debt
$308M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
